## Analysis of Immunomodulating Gene Expression by cDNA Microarray in β-Glucan-treated Murine Macrophage

Su Kyong Sung\* and Ha Won Kim

Department of Life Science, University of Seoul, Seoul 130-743, Korea

β-(1,3)-D-Glucans have been known to exhibit antitumor and antimicrobial activities. The presence of dectin-1,a, \( \beta\)-glucan receptor of dendritic cell, on macrophage has been controvertial. RT-PCR analysis led to the detection of dectin-1a and β in murine macrophage Raw264.7 cell line. Among the various organs of mouse, dectin-1α and β were detected in the thymus, lung, spleen, stomach and intestine. To analyze gene expression modulated by  $\beta$ -glucan treated murine Raw264.7 macrophage, total mRNA was applied to microarray to interrogate the expression of 7,000 known genes. analysis showed that  $\beta$ -glucan of P. osteatus increased gene expressions of immunomodulating genes, membrane antigenic proteins, chemokine ligands, various kinases, lectin associated genes complements, cytokines, oncogenes in Raw 264.7 cell line. When treated with β-glucan of P. osteatus and LPS, induction of gene expression of TNF-a and IFN-R1 was confirmed by RT-PCR analysis. Induction of TNF-R type II expression was confirmed by FACS analysis. IL-6 expression was abolished by EDTA in β-glucan and LPS treated Raw264.7 cell line, indicating that β-glucan binds to dectin-1 in a Ca<sup>\*\*</sup>-dependent manner. To increase antitumor efficacy of β-glucan, ginsenoside Rh2 (GRh2) was co-treated with \( \beta \)-glucan in vivo and in vitro tests. IC<sub>50</sub> values of GRh2 were 20 and 25 ug/ml in SNU-1 and B16 melanoma F10 cell line, respectively. Co-treatment with β-glucan and GRh2 showed synergistic antitumor activity with cisplatin and mitomycin C both in vitro and in vivo. Single or co-treatment with β-glucan and GRh2 increased tumor bearing mouse life span. Co-treatment with β-glucan and GRh2 showed more increased life span with mitomycin C than that with cisplatin. Antitumor activities were 67% and 72 % by co-injection with β-glucan and GRh2 in the absence or presence of mitomycin C, respectively. [This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea. 02-PJ1-PG11-VN01-SV04 -0049]